胆碱酯酶抑制剂改善轻度认知功能障碍患者认知功能有效性及安全性的Meta分析  

Efficacy and safety of cholinesterase inhibitors in treating mild cognitive impairment:A Meta-analysis

作　　者：张文汇[1] 郑媛[1] 卢莎莎[1] 温仲民[1] 

机构地区：[1]苏州大学附属第二医院神经内科,苏州215004

出　　处：《南通大学学报（医学版）》2015年第2期108-113,共6页Journal of Nantong University(Medical sciences)

摘　　要：目的 :系统评价胆碱酯酶抑制剂对轻度认知功能障碍患者认知功能改善的有效性及安全性。方法 :计算机检索CNKI、万方数据库、维普、CBM及Pub Med、Spring Link、Cochrane Library等外文数据库,并通过手工检索,收集胆碱酯酶抑制剂治疗轻度认知功能障碍的随机对照试验,按纳入和排除标准选择文献进行资料提取,使用Cochrane偏倚风险评估工具对入选文献质量进行评价,采用Revman 5.2软件进行Meta分析。结果:共纳入11项随机对照研究,共计4 021例患者,Meta分析结果显示,采用阿尔茨海默病评价量表-认知分表、简易智能量表及蒙特利尔认知评估量表进行治疗前后认知功能改善的评价,两组间差异有统计学意义。不良反应Meta分析结果显示,除抑郁外在腹泻、恶心等方面两组间差异均有统计学意义。"漏斗图"显示,无明显发表偏倚。结论:胆碱酯酶抑制剂对轻度认知障碍患者的认知功能有改善作用,但易导致不良反应发生。Objective： To perform a Meta-analysis of the efficacy and safety of cholinesterase inhibitors（AchEIs） in treating mild cognitive impairment patients（MCI）. Methods： The database of CNKI, Wanfang database, VIP, CBM, PubMed, Spring Link and Cochrane Library were searched for randomized controlled trials（RCTs） about the effect of AchEIs on MCI. The study was screened according to the inclusion and exclusion criteria and then the data were extracted. The methodological quality of included studies was assessed by the Cochrane risk-of-bias tool and Meta-analysis was performed by Revman 5.2 software. Results： 11 RCTs were choosed for this study. Meta-analysis showed that there was a significant difference between the two groups by using the ADAS-Cog, MMSE and MoCA for evaluate the benefits of treatment. Expect for depression, the incidence of nausea、diarrhea and other side effects of AchEIs was higher than placebo group. Conclusion： AchEIs may improve the cognitive function of the patients with MCI, but which leaded to adverse reactions easily.

关 键 词：轻度认知功能障碍 胆碱酯酶抑制剂 META分析 

分 类 号：R749.16[医药卫生—神经病学与精神病学]